ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE

Described herein are antibody-drug conjugates (ADCs) comprising an antibody construct that binds human glypican 3 (GPC3) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer. L'invention concerne des conjugués antico...

Full description

Saved in:
Bibliographic Details
Main Authors RICH, James R, BRANT, Michael G, BARNSCHER, Stuart Daniel, LASALLE, Manuel Michel Auguste, WU, Alex Man Lai, PISCITELLI, Chayne L, ALONZO MUNIZ, Diego Arturo, HERNANDEZ ROJAS, Andrea, PETERSEN, Mark Edmund, UROSEV, Dunja, COLOMBO, Raffaele, DAS, Samir
Format Patent
LanguageEnglish
French
Published 25.04.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Described herein are antibody-drug conjugates (ADCs) comprising an antibody construct that binds human glypican 3 (GPC3) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer. L'invention concerne des conjugués anticorps-médicament (CAM) comprenant une construction d'anticorps qui se lie au glypicane 3 (GPC3) humain conjugué à un analogue de camptothécine de formule (I). Les CAM sont utiles en tant qu'agents thérapeutiques, en particulier dans le traitement du cancer.
Bibliography:Application Number: WO2023CA51378